BioMotiv

BioMotiv is a therapeutic accelerator developing a portfolio of novel medicines. BioMotiv is the mission-aligned development company of The Harrington Project for Discovery and Development. The Harrington Project, unveiled in February by University Hospitals (UH), is a first-of-its-kind $250 million initiative that promises to revolutionize how new breakthrough drugs are advanced to market. By aligning the upstream efforts of the recently created UH Case Medical Center’s Harrington Discovery Institute with the downstream development efforts of BioMotiv, The Harrington Project seeks to accelerate the therapeutic innovation process for the benefit of patients globally. The company was founded in 2012 and is headquartered in Cleveland, Ohio.